Janssen, Legend’s Carvykti approved in US to treat multiple myeloma
In the CARTITUDE-1 study, 98% of patients with RRMM responded to a one-time treatment with Carvykti, while 78%…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Mar 22
In the CARTITUDE-1 study, 98% of patients with RRMM responded to a one-time treatment with Carvykti, while 78%…
28 Feb 22
Through the acquisition, BBL will obtain rights to Viatris’ biosimilars business assets, which is estimated to generate $1bn…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Feb 22
In the CLEAR/KEYNOTE-581 trial, Keytruda plus Lenvima significantly reduced the risk of disease progression or death by 61%,…
25 Feb 22
The FDA approval is supported by results from the Phase 3 EMPEROR-Preserved trial in which Jardiance showed a…
25 Feb 22
Covifenz leverages CoVLP technology, comprises recombinant spike (S) glycoprotein, and is co-administered with GSK’s pandemic adjuvant
24 Feb 22
Sanofi and GSK’s vaccine is said to have induced superior immune responses and a favourable safety profile, both…
24 Feb 22
Thermo Fisher will provide dedicated capacity to scale-up the production of Moderna’s Covid-19 vaccine, and other potential mRNA…
23 Feb 22
The company has a commercial footprint in 56 countries worldwide and is planning to expand its presence in…
22 Feb 22
Corbevax is a receptor-binding domain (RBD) protein sub-unit Covid-19 vaccine and is India’s first indigenously developed Covid-19 vaccine
21 Feb 22
In the interim analysis, Dupixent showed positive results in reducing itch and hives (primary endpoints) but did not…